Xeris turns profitable, files patent suits to defend Recorlev exclusivity through 2040

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Company filed four patent infringement lawsuits against generic manufacturers seeking to market Recorlev before 2040, triggering automatic 30-month FDA approval stays. Success preserves market exclusivity; failure could allow generic competition years earlier.

  Legal Proceedings verify on EDGAR →
• high

  Q1 2026 net income of $2.2M vs. $9.2M loss prior year, driven by 95% Recorlev revenue growth ($24.2M increase) and 230-basis-point gross margin improvement. Operating cash flow turned positive at $9.9M vs. $10.0M burn.

  MD&A: Financial Results verify on EDGAR →
• high

  Patent portfolio expanded from 167 to 181 patents, including new Orange Book-listed Recorlev patent (No. 12,377,096) granted August 2025, extending protection through 2040 and strengthening competitive moat.

  MD&A: Intellectual Property verify on EDGAR →